Navigation Links
LifeCare Holdings, Inc. Names McAlister Chairman and CEO
Date:4/15/2008

New president and chief financial officer also appointed

PLANO, Texas, April 15 /PRNewswire/ -- Wayne McAlister has been named chairman and chief executive officer of LifeCare Holdings, Inc., a 20-facility long term acute care hospital system based in Plano, Texas. Chief Financial Officer Phillip B. Douglas has been promoted to president of the company, and Chris A. Walker, formerly chief accounting officer, will now serve as CFO.

McAlister is a seasoned hospital operations executive with more than 38 years experience. He joined LifeCare earlier this year as president and CEO. McAlister was previously senior vice president and division president for Triad Hospitals, Inc., overseeing development, management and financial operations for a large group of hospitals. He has also held senior management positions with Paracelsus Healthcare Corporation, Tenet Healthcare Corporation and Charter Medical Corporation. McAlister currently serves on the board of directors for the Acute Long Term Hospital Association; he is a former member of the board of governors of the Federation of American Hospitals and a former member of the board of trustees of the National Association of Private Psychiatric Hospitals.

A healthcare executive and entrepreneur with 28 years experience, Phil Douglas has served as LifeCare chief financial officer since January 2006. Prior to joining LifeCare, he held senior management positions with several healthcare and IT solutions companies, including UnitedHealth Group and Humana Inc. Douglas founded health information technology company Management and Technology Solutions, Inc., which was acquired by the TriZetto Group. He also co-founded HealthSpring, a physician practice management company that was acquired by the MetraHealth Companies, which was ultimately acquired by UnitedHealth Group; Douglas served as senior vice president of finance for the combined companies from 1995 to 1996. Douglas currently serves on the boar
'/>"/>

SOURCE LifeCare Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. LifeCare Holdings, Inc. Announces Year-end Results
2. LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing
3. LifeCare Holdings, Inc. Announces Third Quarter Results
4. Duane Reade Holdings, Inc. Announces Resignation of Chief Marketing Officer
5. China Shenghuo Pharmaceutical Holdings, Inc. to Present at Brean Murray Carret & Co. Mainland China Investor Tour
6. Hill-Rom Holdings, Inc. Announces Completion of Separation of Hillenbrand Industries Creating Two Public Companies
7. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
8. Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources
9. Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market
10. Solera Holdings, Inc. Appoints Jason Brady as General Counsel
11. Duane Reade Holdings, Inc. to Report Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...re inequalities may have the most significant impa...cancer (CRC) between African// Americans and Cauca...June 1, 2007 issue of CANCER, a peer-reviewed jour...is of data from published studies demonstrated tha...
... a handful of concerned citizens. Delhi, burning u...h Day Sunday, //by raising its voice on various is... are on the brink of a challenge,' said Ravi Aggar...GO. 'The issue of stopping deforestation and felli...
...ted with an electronic biometric attendance system...l be initially installed in a few primary schools,...state. It would first be installed in 15 schools o...f Dausa. 'Some of the machines have already reach...
...ion drive aimed at protecting millions of children...ealth experts, nearly 10% of the// children could ...f Health is conducting the MMR (measles, mumps and...will be on for two weeks. This is being funded by ...
Other Medicine News:Health News:Social Factors Not Genetics Drive Racial Disparities in Colorectal Cancer Survival 2Health News:Earth Day Celebrated With Hopes of a Greener Tomorrow 2
(Date:9/3/2008)...SELS, Belgium and GENEVA, Sept. 3 /- ...lestone in CHO based monoclonal antibody,productio...over 31 grams,per liter. This record level was acc...logies: (1) a high-performance stable Selexis CHO,... leading scientists at,Selexis SA using their prop...
(Date:9/3/2008)... Company to Discuss Phase 3 Plans with FDA...Therapeutics, Inc.,announced today that it succes...velopment of the company,s new, innovative low-dos...pany refers to by its internal product,code AG-200...sfully met its,primary endpoint of ovulation suppr...
(Date:9/3/2008)...509 to be Evaluated in Repeat-Dosing Study in Subj...ire-FirstCall/ -- Sangamo,BioSciences, Inc. (Nasda...ase,2 clinical trial (SB-509-801) to evaluate its ... degenerative motor-neuron disease for which there...amo,s drug, SB-509, is an injectable formulation o...
(Date:9/2/2008)...S, September 3 /-, - This ...ased the Risk,of Stroke by 34% in Patients With At...tely Treated by Antithrombotic Therapy, The resul...ENA study,were presented today at the clinical tri...ology congress 2008, in Munich, Germany. Previous ...
Breaking Medicine Technology:Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Amira Pharmaceuticals Appoints First Vice President of Development 5214 1Amira Pharmaceuticals Appoints First Vice President of Development 5214 2Agingcare com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 5211 1Agingcare com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 5211 2Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 1Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 2Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 3Spinal Stem Cells Offer Hope Against Back Pain 5205 1Spinal Stem Cells Offer Hope Against Back Pain 5205 2
...New Studies Confirm That Fusion Proteins Made by C...dies Demonstrate Increased,Anti-Tumor Activity Wit..., Calif., April 18, 2007,/PRNewswire-FirstCall/ --...e biopharmaceutical company developing targeted,mo...d hepatitis C,virus infection, today reported that...
...AITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2...edImmune, Inc. today,announced data from a preclin...rcinoembryonal antigen (CEA) were shown to prevent...etastases. An,established marker for tumor progres... and other human carcinomas. These data,presented...
Other Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 2Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 3Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 2Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 3Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 5
...ries Freezing Stages fit easily onto most microtom...arts and need only the AC supply and a trickle of ...ediately and can be maintained indefinitely. Stag...g temperatures can be set for different kinds of t...
ELISA kit for the quantitative determination of autoantibodies to glutamic acid decarboxylase (GAD65) in serum
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum
RIA kit for the quantitative determination of autoantibodies to insulin in serum
Medicine Products: